疏肝导浊方药含药血清对HepG2细胞PPARα、HL及载脂蛋白表达的影响  

Effects of Shugandaozhuo prescription-containing Serum on expression of PPARα,HL apolipoprotein B100,AII,CII mRNA of hepatic cell Line of hepG2

作　　者：王威[1] 江海涛[1] 史红[1] 刘友刚[1] 王超[1] 田维[1] 胡利民[1] 

机构地区：[1]天津中医药大学,300193

出　　处：《天津中医药大学学报》2009年第4期182-184,共3页Journal of Tianjin University of Traditional Chinese Medicine

基　　金：国家科技部支撑计划;名优中成药大品种二次开发关键技术的研究项目(2007BAI47B04)

摘　　要：[目的]观察疏肝导浊方药含药血清对肝癌细胞株(HepG2)细胞株的过氧化物酶体增殖物激活受体(PPARα),肝脂酶(HL)及载脂蛋白ApoB100,ApoAII,ApoCIImRNA表达的影响,探讨其治疗脂肪肝的机制。[方法]以HepG2细胞株为研究对象,采用血清药理学方法,将含药血清分为高、中、低(16,8,4g/kg)剂量组、东宝肝泰对照组、模型组和空白对照组,研究疏肝导浊方药对HepG2细胞株PPARα及载脂蛋白的mRNA表达的影响。[结果]表明疏肝导浊方药含药血清能增加HepG2细胞PPARα、HL、ApoB100,ApoAII,ApoCIImRNA的表达。[结论]疏肝导浊方药含药血清提高了PPARα、HL及载脂蛋白ApoB100,ApoAII,ApoCIImRNA的表达,从而促进了肝细胞的脂代谢功能这可能是疏肝导浊方药治疗脂肪肝的重要机制之一。[Objective] To observe the effects of Shuogandaozhuo prescription on the expression of PPARα,HL and apolipoprotein B100,ApoAII,ApoCIImRNA in HepG2 in vitro and explore the mechanism for treating fatty liver.[Methods] HepG2 Cells in vitro were chosen as the study object and the experiments were divided into six groups：the shugandaozhuo-containing serum groups high dose 16 g/ （kg·d）,middle dose 8 g/（kg·d）,low dose 4 g/（kg·d）,the Dongbaogantai group,the model group and the normal group. The experimental method was using the serology pharmacology. [Results] The shugan-daozhjuo-containing serum could increase the expression of PPARα,HL and apolipoprotein B100,APOAII,ApoCIImRNA of hepatic cell line of HepG2. [Conclusion] It may be one of the mechanism for treating hyperlipemia syndrome and coronary heart disease.

关 键 词：疏肝导浊方药 HEPG2细胞 过氧化物酶体增殖物激活受体(PPAR) 载脂蛋白 

分 类 号：R289.5[医药卫生—方剂学]